Full Press Release Details
Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36
Associated Inflammatory Model
ANGELES - May 27, 2026 - Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing
localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article
in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36-associated inflammatory
publication, titled "Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model
characterized by IL-36 expression," was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen
Bresnick, M.D., a practicing physician, researcher, and advisor to the Company.
publication demonstrates a shift in how inflammatory skin disease should be studied. Rather than inferring biology from systemic markers,
we evaluated GX-03 directly within an IL-36-associated inflammatory environment and observed a clear clinical effect following
seven days of twice-daily treatment," said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. "This is about building
a more precise understanding of what is driving inflammation in the skin, at the site of disease. We're helping define a framework
for evaluating targeted, localized therapies in dermatology."
is a cytokine associated with epithelial stress and is minimally expressed in healthy skin but becomes upregulated in response to microbial
dysbiosis and barrier disruption. The study confirmed reproducible IL-36 expression following Staphylococcus aureus exposure, establishing
a relevant inflammatory context in which GX-03 demonstrated clinical activity. This publication supports the Company's broader
approach of targeting disease at the site of origin.
The article represents the first in a planned
series of scientific publications evaluating GX-03's clinical and biological activity, with a subsequent manuscript already in
review characterizing the mechanistic implications of treatment.
is a first-in-class, non-systemic, topical cytokine-modulating therapy in development for moderate-to-severe atopic dermatitis (eczema).
By stabilizing the cutaneous microenvironment and modulating epithelial danger sensing, GX-03 is designed to address IL-36, IL-4, IL-13,
and IL-31 signaling through upstream prevention rather than downstream, systemic suppression. GX-03 is currently being evaluated in a
Phase 2 randomized controlled trial, with topline results expected in mid-2026.
Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes
of inflammatory diseases with high unmet needs. Its lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor
currently in development for the treatment of moderate-to-severe atopic dermatitis. This therapy is designed to modulate key inflammatory
pathways involved in eczema and other inflammatory dermatological conditions, specifically targeting IL-36 and IL-31, two cytokines that
play distinct but interconnected roles in driving chronic skin inflammation and the itch-scratch cycle. GX-03 addresses IL-36 upstream,
where epithelial stress and barrier disruption initiate the inflammatory cascade, and IL-31 downstream, where itch signaling perpetuates
disease. It is currently being evaluated in a Phase 2 randomized controlled trial, with topline results expected in mid-2026.
B, Bresnick S. Effects of Extended-Release Topical Polyhexanide in a Staphylococcus aureus-Induced Murine Dermatitis
Model Characterized by IL-36 Expression. Journal of Dermatological Treatment. 2026. Article ID: IJDT 2667686. DOI: https://doi.org/10.1080/09546634.2026.2667686
statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"suggest," "target," "aim," "should," "will," "would," or the
negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking
statements are based on Turn's current expectations and are subject to inherent uncertainties, risks, and assumptions that are
difficult to predict, including risks related to the success of development programs, and the Company's ability to execute its
strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.
For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company's
filings with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K
for the year ended December 31, 2025, filed with the SEC on March 31, 2026. All such forward-looking statements speak only as of the
date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future
events, or otherwise.
Relations / Media Contact